Pathway -terminal Kinase 2 Partly via Blockade of C-jun Nh Α Activated Receptor- − Proliferator Induced Cardiac Hypertrophy Is Inhibited by Activation of Peroxisome − Endothelin-1 Endothelin-1–induced Cardiac Hypertrophy Is Inhibited by Activation of Peroxisome Proliferator–activated Receptor-␣ Part

Background—Peroxisome proliferator-activated receptor-&agr; (PPAR-&agr;) is a lipid-activated nuclear receptor that negatively regulates the vascular inflammatory gene response by interacting with transcription factors, nuclear factor-&kgr;B, and AP-1. However, the roles of PPAR-&agr; activators in endothelin (ET)-1–induced cardiac hypertrophy are not yet known. Methods and Results—First, in cultured neonatal rat cardiomyocytes, a PPAR-&agr; activator, fenofibrate (10 &mgr;mol/L), and PPAR-&agr; overexpression markedly inhibited the ET-1–induced increase in protein synthesis. Second, fenofibrate markedly inhibited ET-1–induced increase in c-Jun gene expression and phosphorylation of c-Jun and JNK. These results suggest that this PPAR-&agr; activator interferes with the formation and activation of AP-1 protein induced by ET-1 in cardiomyocytes. Third, fenofibrate significantly inhibited the increase of ET-1 mRNA level by ET-1, which was also confirmed by luciferase assay. Electrophoretic mobility shift assay revealed that fenofibrate significantly decreased the ET-1–stimulated or phorbol 12-myristate 13-acetate–stimulated AP-1 DNA binding activity, and the nuclear extract probe complex was supershifted by anti-c-Jun antibody. Fourth, 24 hours after aortic banding (AB) operation, fenofibrate treatment significantly inhibited left ventricular hypertrophy and hypertrophy-related gene expression pattern (ET-1, brain natriuretic peptide, and &bgr;-myosin heavy chain mRNA) in AB rats. Conclusions—These results suggest that PPAR-&agr; activation interferes with the signaling pathway of ET-1–induced cardiac hypertrophy through negative regulation of AP-1 binding activity, partly via inhibition of the JNK pathway in cultured cardiomyocytes. We also revealed that fenofibrate treatment inhibited left ventricle hypertrophy and phenotypic changes in cardiac gene expression in AB rats in vivo.

[1]  Richard T. Lee,et al.  Peroxisome Proliferator-Activated Receptor &ggr; Activators Inhibit Cardiac Hypertrophy in Cardiac Myocytes , 2001, Circulation.

[2]  M. Karin,et al.  Requirement for p38α in Erythropoietin Expression A Role for Stress Kinases in Erythropoiesis , 2000, Cell.

[3]  I. Yamaguchi,et al.  Long-term endothelin receptor antagonist administration improves alterations in expression of various cardiac genes in failing myocardium of rats with heart failure. , 2000, Circulation.

[4]  Frank J. Gonzalez,et al.  Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1* , 1999, The Journal of Biological Chemistry.

[5]  Y. Kakinuma,et al.  Myocardial expression of endothelin-2 is altered reciprocally to that of endothelin-1 during ischemia of cardiomyocytes in vitro and during heart failure in vivo. , 1999, Life sciences.

[6]  B. Staels,et al.  Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. , 1999, Circulation research.

[7]  P. Sugden,et al.  Signaling in myocardial hypertrophy: life after calcineurin? , 1999, Circulation research.

[8]  T. Masaki,et al.  Pathophysiology of endothelin in the cardiovascular system. , 1999, Annual review of physiology.

[9]  A. Clerk,et al.  Stimulation of the p38 Mitogen-activated Protein Kinase Pathway in Neonatal Rat Ventricular Myocytes by the G Protein–coupled Receptor Agonists, Endothelin-1 and Phenylephrine: A Role in Cardiac Myocyte Hypertrophy? , 1998, The Journal of cell biology.

[10]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[11]  Y. Sugishita,et al.  Inhibition of myocardial endothelin pathway improves long-term survival in heart failure , 1996, Nature.

[12]  P. Sugden,et al.  Cellular Stresses Differentially Activate c-Jun N-terminal Protein Kinases and Extracellular Signal-regulated Protein Kinases in Cultured Ventricular Myocytes (*) , 1995, The Journal of Biological Chemistry.

[13]  M. Karin.  The Regulation of AP-1 Activity by Mitogen-activated Protein Kinases (*) , 1995, The Journal of Biological Chemistry.

[14]  K. Umesono,et al.  Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Y. Sugishita,et al.  Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. , 1993, Circulation research.

[16]  Y. Sugishita,et al.  Increased production of endothelin‐1 in the hypertrophied rat heart due to pressure overload , 1993, FEBS letters.

[17]  I. Issemann,et al.  The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. , 1992, The EMBO journal.

[18]  I. Issemann,et al.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.

[19]  Y. Mitsui,et al.  Endothelin stimulates hypertrophy and contractility of neonatal rat cardiac myocytes in a serum‐free medium , 1990, FEBS letters.

[20]  P. Hatt,et al.  Rat myocardial mechanics during pressure-induced hypertrophy development and reversal. , 1975, The American journal of physiology.